ABSTRACT
A cytokine screening assay of cultured peripheral blood cells obtained using immune rosetting and separation of progenitors was developed to identify determinants of fetal hemoglobin (HbF) modulation during adult erythropoiesis.
Among the twelve erythroid growth-promoting cytokines tested, stem cell factor (SCF) at a concentration of 50 ng/mL resulted in the most significant increase in cell proliferation and HbF content. The average HbF:HbA ratio was 30.9 + 18.7% in cultures containing SCF compared with 4.1 + 2.2% in those grown with erythropoietin (EPO) alone (p value=8.5E-8). To further investigate the hemoglobin-modulating effects of SCF, we examined the surface expression pattern of the SCF receptor, CD117, among maturing erythroblasts. CD117 expression increased during the first week of culture and peaked on culture days 7-9. After culture day 9, the level of CD117 declined to lower levels. The rise in CD117 expression to high levels mirrored that of the transferrin receptor (CD71), and the subsequent reduction in CD117 was inversely related to increases in glycophorin A (GPA) expression. SCF related increases in the HbF:HbA ratio correlated with the expression pattern of CD117. SCF added during days [7] [8] [9] [10] [11] [12] [13] [14] resulted in a more pancellular distribution of HbF on day 14 compared with the heterocellular distribution present in cultures supplemented with SCF on days 0-7. A significant SCF-mediated increase in HbF was also measured using cord blood derived progenitors. These results suggest that the HbF response to SCF is greatest at the late progenitor stage as a function of surface CD117 expression.
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INTRODUCTION
A complete understanding of fetal hemoglobin (HbF) production among adult erythroblasts is critical for the treatment of sickle cell anemia and beta thalassemia. Fetal hemoglobin prevents HbS polymerization in all newborns until HbS becomes the dominant hemoglobin in circulating erythrocytes (1) . HbF levels of >25% also prevent sickling in a subset of patients with S-deletion form of HPFH. A "benign" form of sickle cell anemia among adults in eastern Saudi Arabia has further been attributed to elevated levels of HbF (2, 3) . Pharmacologic induction of fetal hemoglobin has favorably influenced the course of disease in patients with sickle cell diseases and beta thalassemia (4, 5) . For these reasons, efforts aimed at the clinical augmentation of HbF during adult erythropoiesis continue to be an active focus of research (6) .
"Switching" of the dominant hemoglobin in circulating erythrocytes from the fetal to adult type is usually completed during infancy. However, some individuals continue to have increased expression of fetal hemoglobin later in their lives (7) . In many cases, those individuals possess elevations in HbF content due to large deletions involving the beta globin locus on chromosome 11.
Other individuals possess defined mutations within regulatory regions of that locus (8) . Those mutations have led to the general conclusion that DNA -binding proteins and chromatin structure are important determinants of gamma-globin gene transcription during adult life. Other families have elevations in fetal hemoglobin that are linked to separate genomic regions (9) (10) (11) . Recognition that certain forms of leukemia are associated with higher levels of HbF suggests nonglobin genes involved in erythroid growth or leukemogenesis may regulate globin gene transcription (12) . In addition to malignant transformation, it has long been recognized that conditions of acute erythroid stress are associated with elevated HbF levels (13) . Kinetic models have been proposed to explain this phenomenon (14) , but a molecular mechanism has not yet been defined. Several investigators have attempted to reproduce this stress response in vitro using growth-related cytokines. While strong correlations between cytokine supplementation and HbF For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From production have been reported (15) , those results are challenged by others (16) .
SCF has been most well studied and is thought to influence HbF production through signaling at the very early stages of erythropoiesis (17) (18) (19) .
In this report, we compare a dozen hematopoietic growth-promoting cytokines for their HbF modulating effects by screening matched cultures of primary human erythroblasts. SCF produced the most significant and consistent increase in the HbF content in the cells of several donors. While an SCF response was consistently demonstrated, the absolute increase in HbF:HbA varied considerably among donors. SCF was further examined to determine whether effects on HbF were varied according to erythroid development and maturation. SCF effects on HbF appeared to be greater at later stages of erythroblast maturation and correlated well with a highly regulated pattern of CD117 (c-kit; stem cell factor receptor) expression. A significant SCF effect upon HbF was also detected using cord blood derived progenitor cells. Purified hemoglobin F and A (Perkin-Elmer Wallack, Norton, OH) were used for reference.
MATERIALS AND METHODS

Culture
RESULTS
Screening assay of growth-associated cytokines. For the purpose of screening cytokines and other biologically active molecules for possible effects on hemoglobin modulation during erythropoiesis, we used a single-phase culture system of progenitor cells from the buffy coats of normal blood donors. This single-phase culture system used negative selection as the method for obtaining progenitor cells, and the cells were obtained from the buffy coats of blood donations rather than mobilized aphaeresis products as we have previously described (20) . Once isolated, the cell populations were cultured at an initial concentration of approximately 10(4) cells /ml for 14 days in EPO-containing (4U/ml) medium. After 14 days, the cells were counted and the ratio of fetal and adult hemoglobin (HbF:HbA) was determined on the basis of HPLC analyses. In cultures supplemented with EPO alone and no additional cytokines, an average of 8 million erythroid precursor cells per unit of donated blood (3.8 + 0.2E05 cells/ml culture medium) were generated after the 14 day culture period. Overall, the HbF:HbA ratio averaged 3.9 + 0.2% after the 14 day culture period in EPO without additional cytokines. (Table 1) . For this study, a dozen cytokines were screened on the basis of previous reports suggesting a possible association with erythroid growth using other culture systems. In cases where previous reports were unavailable, the cytokines were added at low and high concentrations for measurement of a possible dose effect (higher concentrations shown in the Table 1 persisted on day 9, they were no longer detected by day 12. When EPO and SCF were added on day 0, the CD117 signal remained low for the first 48 hours followed by a delayed increase during the first week and lower peak levels compared to cells cultured in EPO alone. In triplicate analyses, the mean CD117
fluorescence on culture day 6 in EPO alone was 13. 
DISCUSSION
In this report, we have begun to explore the hypothesis that fetal hemoglobin modulation may result from signal transduction involving fully committed erythroblasts. This hypothesis arose from the demonstration that HbF and HbA share a coordinated rather than "switched" expression pattern during adult human erythropoiesis (20) . Our matched culture strategy using primary cells from peripheral blood was developed to screen several growth-related cytokines for possible effects on hemoglobin modulation. In the absence of additional cytokines, the progenitor cells from those normal blood donors proliferated and differentiated into populations containing > 95% GPA(+) erythroblasts with a HbF:HbA of <5% after 14 days in EPO-supplemented culture medium. Of note, these results using mononuclear cells from a relatively large number of blood donations demonstrated a nearly identical in vitro pattern of erythroid development to that of mobilized CD34(+) cells (20) . Several of the tested cytokines did not significantly affect hemoglobin modulation with the screening assay described here, but formal dose titration and cytokine combinations must be performed before their effects on erythropoiesis are fully understood. As an initial screen, this primary cell culture system appears to be well suited for testing other cytokines, pharmacological agents, or mixtures thereof. Among the cytokines demonstrating significant effects on hemoglobin modulation, SCF was studied further based upon its dramatic effects on HbF and cell proliferation as shown here and elsewhere (17) (18) (19) . SCF caused a consistent rise in the HbF:HbA among 19 normal blood donors, but the magnitude of the SCF response was highly variable. Host response variability has similarly been identified in the response of HbF-modulating agents used in patients with hemoglobinopathies (23, 24) .
The flow cytometric analyses of the SCF receptor (CD117) expression demonstrated a highly regulated pattern during human erythropoiesis. Of For personal use only. on November 12, 2017. by guest www.bloodjournal.org From particular interest was the demonstration of increased CD117 expression to higher levels coincidental with the rise in CD71 expression. Initial increases in CD117 expression were followed several days later by a decline to lower levels associated with the expression of GPA at high levels on the erythroblast surface.
Hence, the highest level of CD117 expression was present in cells having a CD71 (high), GPA (low) cellular phenotype. This phenotype has been previously shown to identify committed, rapidly proliferating erythroblasts (20) . The increased expression of CD71 also correlates with the onset of hemoglobin production at low levels in each cell (20) . Consistent with the increased level of CD117, cells at this developmental stage also appear to be the most sensitive to SCF (compare Figures 4 and 5) . Furthermore, the decline of CD117 from the cell surface toward the end of the culture period corresponded to a loss of SCF effect. We conclude that CD117 expression is highly regulated during erythroid differentiation, and that the magnitude of SCF-mediated effects is proportionate to the extent of CD117 expression on the cell surface. While not studied here, others have shown that HbF-modulating effects of SCF on erythroblasts are maintained in circulating erythrocytes in vivo (25) .
While designing these studies, we predicted that increases in the HbF:HbA ratio would be greatest after continuous exposure to SCF on days 0-14. However, cells cultured in the same concentration of SCF only during the second week resulted in higher HbF:HbA ratios at the end of the 14-day period.
This unexpected result may be related to the initial loss of SCF-bound CD117 from the cell surface. After SCF dimerizes CD117 on the cell surface, the receptor-ligand complexes are internalized and degraded (21) . Unlike the recycling of transferrin receptor to the cell surface after transferrin internalization, CD117 is not recycled and receptor levels on the cell surface are down regulated until new CD117 is produced. We speculate that the internalization SCF-CD117 complexes from the surface of immature cells provide an autoregulatory mechanism for SCF effects in more mature human erythroblasts. This type of ligand-dependent regulation of receptor expression in erythroblasts could provide the basis for differences in the HbF production associated with acute and chronic
states of stress or other transitions in hemoglobin production (14) . Whether the high serum SCF levels associated with stress erythropoiesis in humans (27) correlates with lower CD117 levels in bone marrow erythroblasts is unknown.
HbF modulation during erythroid stress in vivo will likely involve additional factors including signaling from both soluble and transmembranous forms of SCF, local concentrations of additional cytokines, and interactions between erythroblasts and other cells in the marrow.
We were unable to identify any special population of erythroid progenitors that were recruited by the addition of SCF during the earliest period of erythroid development. The HbF distribution in the presence of SCF during the first week was nearly identical to that of cells cultured in EPO alone (Figure 4 ). This result challenges the assumption that hemoglobin-modulating effects of SCF are greatest at the earliest stages of erythropoiesis. In this study, the most significant effect of SCF upon the fetal hemoglobin modulation occurred in late progenitors as CD117 increased just prior to the terminal stages of differentiation. This "late" effect of SCF in human cells was not predicted from nonhuman models, since EPO downregulates the expression of c-kit among murine progenitor cells within 3 hours (26) . SCF altered the erythroid program of the adult cells as reflected by the significant increase in the HbF:HbA ratio and the increased distribution in HbF. In cord blood derived populations, the HbF:HbA ratio rose to HbF-dominant levels. In addition, the response in cord blood derived progenitor cells suggest that SCF modulates hemoglobin by increasing its expression in cells already producing the protein in addition to the "reactivation" of HbF in adult cells.
The developmental program of committed human erythroblasts is neither fixed nor determined exclusively by erythropoietin. Germline mutations in either murine SCF (steel factor) or CD117 (c-kit) result in severe anemia in the mouse (28) . Multiple intracellular signaling pathways are involved in the SCF response primarily through the control of gene transcription (29, 30) . In erythroid cells, integration of EPO and SCF signaling may occur at the level of their membrane receptors (31) or within downstream pathways (32) . The first evidence that SCF possessed hemoglobin-modulating properties in addition to its effect on erythroid For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From growth was derived from in vitro assays using the cells of patients with sickle cell disease (17) . Though questioned by some (27, 33) , these results have been reproduced here and by others (18, 25) . Recently, an elegant unicellular system has been reported to demonstrate clonal SCF-mediated HbF modulation at very early stages of erythropoiesis (19) . Our data suggest that SCF effects on fetal hemoglobin are not restricted to the earliest erythroblasts, but may be even more dramatic among more mature erythroblast populations as a function of increased CD117 expression on their membranes. We propose that consecutive generations of human erythroblasts possess hemoglobin programs that are dynamic and determined, at least in part, by the environment in which those cells arise.
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